Cardiovascular Health

SGLT-2 inhibitors reduce cardiovascular deaths, heart failure hospitalizations, hyperkalemia, and decline of renal function in patients with HFrEF.

Bristol Myers Squibb will also present findings on apixaban (Eliquis) at the American College of Cardiology Annual Scientific Session and Expo.

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.

The finding did not reach statistical significance in the primary composite endpoint.

The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

The Librexia program includes 3 concurrent clinical trials, investigating milvexian’s use for ischemic stroke, acute coronary syndrome, and atrial fibrillation

Investigators also found that African American and White veterans had different risk factors for re-hospitalization post-stroke.

Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.

Interactions between nirmatrelvir/ritonavir and direct oral anticoagulants is complicated, and a point of contrasting views between the US and EU medical communities.

An overview of the use of direct oral anticoagulants as an alternative to warfarin in the treatment of left ventricular thrombus.

Sotatercept-csrk is the first approved activin signaling inhibitor therapy for pulmonary arterial hypertension, which represents a new class of therapy.

All 20 participants in a 12-month follow-up study attained acute success from ablation procedures.

The combination tablet (Opsynvi; Johnson & Johnson) can also be used for individuals with pulmonary arterial hypertension who are being treated with stable doses of macitentan and tadalafil as separate tables.

Bempedoic acid (Nexletol; Esperion) and bempedoic acid and ezetimibe (Nexlizet; Esperion) are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.

The FDA has only approved aprocitentan (Tryvio; Idorsia) in the 12.5 mg dosage as the effects were similar between the 25 mg and 12.5 mg dosages.

Team-based care models improve continuity of care and accessibility for patients.

The disease is complex, but many opportunities exist for pharmacist intervention.

Although newly approved, there is some debate regarding the benefits and populations in which sotagliflozin will be the most effective.

Pharmacogenomic information can be used to more selectively choose medications and doses that are more appropriate for each individual.

Semaglutide (Wegovy; Novo Nordisk) reduces the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight when combined with the standard-of-care.

Artificial intelligence (AI) recommendations resulted in fewer recurrent strokes, heart attacks, or vascular death within 3 months of a previous ischemic stroke.

According to the researchers, making changes to the daylight saving time system to accommodate heart health is unnecessary.

The effects of acupuncture were independent of sex, age, medication use, and coexisting conditions, according to the results of the study published in BMJ Open.

The investigators included 24 studies across 7 countries, including Australia, Canada, New Zealand, Norway, Singapore, Sweden, and the United States.